Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050853 · ClinicalTrials.gov registry record · NA
The Appeal and Impact of E-cigarettes in Smokers With SMI
A NA study of Schizophrenia and Bipolar Disorder, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 2
- Study locations
NCT03050853: Completed NA study of Schizophrenia and Bipolar Disorder, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03050853 is a NA study of Schizophrenia and Bipolar Disorder that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 240 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (10% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03050853, a NA study of Schizophrenia and Bipolar Disorder, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate behavioral and psychological appeal, toxicity, and effect of e-cigarettes on smoking behavior and nicotine addiction in chronic smokers with serious mental illness (SMI) who have failed to quit smoking. A total of 240 participants will be enrolled and randomly assigned to either receive a supply of e-cigarettes for 8 weeks plus assessments (baseline \& weeks 2, 4, 6, 8, 13, \& 26) or assessments only. This single-blinded study will provide e-cigarettes and instructions on their safe use. Level of appeal will be inferred from carefully assessed use of e-cigarettes and reduction in combustible tobacco. Qualitative data will also be collected from participants assigned to e-cigarettes, given that unanticipated issues will almost certainly arise in connection with e-cigarette use that can only be captured within a qualitative debriefing at the conclusion of participants' time in the study.
Primary Outcome
Carbon Monoxide Measurement
Conditions Studied
Interventions
- BEHAVIORAL E-cigarette
Study Locations (2)
Kentucky
- Centerstone Kentucky - Louisville
Massachusetts
- Vinfen Corp - Lawrence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2021-01-31 |
| Phase | NA |
What the finished NCT03050853 record still lists
NCT03050853 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (10% higher).
The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which E-cigarette is the first listed.
NCT03050853 reports a single indexed study location in Kentucky, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03050853 about?
NCT03050853 is a clinical study titled "The Appeal and Impact of E-cigarettes in Smokers With SMI". This study will evaluate behavioral and psychological appeal, toxicity, and effect of e-cigarettes on smoking behavior and nicotine addiction in chronic smokers with serious mental illness (SMI) who have failed to quit smoking. A total of 240 participants will be enrolled and randomly assigned to ei...
What is the current status of trial NCT03050853?
This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2017-03-01. Estimated completion is 2021-01-31.
What conditions does trial NCT03050853 study?
This clinical trial studies the following conditions: Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Tobacco Dependence.
What interventions are being tested in trial NCT03050853?
The interventions under investigation include: E-cigarette (BEHAVIORAL).
Who is sponsoring clinical trial NCT03050853?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03050853 being conducted?
This trial has 2 study locations across Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03050853's enrollment target sits among peer trials
240 80th of 315 higher than 236 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI